| Oct 18 |
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
|
| Oct 9 |
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
|
| Oct 9 |
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
|
| Oct 7 |
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
|
| Oct 4 |
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
|
| Sep 26 |
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback
|
| Sep 24 |
Fulcrum reduces its workforce
|
| Sep 20 |
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
|
| Sep 17 |
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
|
| Sep 16 |
Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
